The potential of CpG-enhanced plasmid DNA vectors encoding a truncated secreted form of bovine herpesvirus-1 (BHV-1) glycoprotein D (tgD) to induce enhanced immune responses in cattle was investigated. We created tgD expression plasmids containing 0, 40 or 88 copies of the hexamer 5h GTCGTT 3h, a known pan-activating CpG motif in several species. The total tgD-specific IgG titre of calves immunized with these plasmids did not correlate with the CpG content of the plasmid backbone. However, the pBISIA88-tgD-vaccinated group showed a significantly lower IgG1 : IgG2 ratio than calves immunized with pBISIA40-tgD or pMASIA-tgD, which has no CpG motifs inserted. Antigen-specific lymphocyte proliferation and IFN-γ secretion by peripheral blood mononuclear cells correlated positively with the CpG content of the vectors. In contrast, calves that received a killed BHV-1 vaccine had an IgG1-predominant isotype and low lymphocyte proliferation and IFN-γ levels. Following challenge, the pBISIA88-tgD-immunized group developed the greatest anamnestic response, the highest BHV-1 neutralization titres in serum and a significantly lower level of virus shedding than the saline control group. However, there were no significant differences in clinical symptoms of infection between the DNA-immunized groups and the saline control group. These data indicate that CpG-enhanced plasmids induce augmented immune responses and could be used to vaccinate against pathogens requiring a strong cellular response for protection.
Introduction
It is well established that the innate immune system of vertebrates recognizes unmethylated cytidine-phosphateguanosine (CpG) dinucleotides flanked by specific bases in bacterial DNA as a danger signal (Krieg, 2000 ; Krieg & Davis, 2001 ; Krieg et al., 1995) . It has been proposed that the uptake of DNA occurs via scavenger receptors and that CpG motifs are specifically recognized by Toll-like receptor 9, which is located on lysozomes (Hemmi et al., 2000 ; Schnare et al., 2000) . The cytokine profile induced by CpG motifs in vitro is consistent with their ability to induce a Th1-biased immune response when used as an adjuvant in vaccine formulations. Therefore, CpG motifs may have potential as an adjuvant in protein-and DNA-based vaccine formulations (Klinman et al., Author for correspondence : Sylvia van Drunen Littel-van den Hurk.
Fax j1 306 966 7478. e-mail vandenhurk!sask.usask.ca 2000 ; Krieg et al., 1998b ; McCluskie et al., 2000) . There has been substantial work on DNA immunization in many species, including humans and large animals Roy et al., 2000 ; van Drunen Littel-van den Hurk et al., 2000 , 2001 . While there is some limited information concerning the biological effects of CpG motifs in cattle (Brown et al., 1998 ; Pontarollo et al., 2002 ; Shoda et al., 2001) , the adjuvant role of CpG motifs, either alone in an oligodeoxynucleotide (ODN) or as part of the vector backbone, is just starting to be studied in species other than mice and humans (Kamstrup et al., 2001 ; Rankin et al., 2001 Rankin et al., , 2002 .
Bovine herpesvirus 1 (BHV-1) is an economically important pathogen in cattle and is commonly associated with the bovine respiratory disease complex and abortion (Yates, 1982) . Moderately effective killed and modified-live BHV-1 vaccines are available, and a subunit vaccine using truncated glycoprotein D (tgD) has been developed (Harland et al., 1992 ;  van Drunen Littel-van den Hurk et al., 1993) . DNA immu-nization against BHV-1 has been demonstrated in cattle, and partial protection from challenge has been achieved (Braun et al., 1999 ; Loehr et al., 2000) . However, there is a need to improve the efficacy of these vaccines. As an approach to augment the effectiveness of tgD-encoding plasmids as a vaccine, we have modified the vector backbone by adding a controlled number of CpG motifs. Here we describe the first use of CpG-enhanced vectors in a vaccine formulation against a pathogen that causes significant economic loss in the target species.
Methods
Cell lines and viruses. BHV-1 strains 108 and Cooper were propagated in bovine viral diarrhoea virus-free Madin-Darby bovine kidney (MDBK) cells cultured in minimal essential medium (MEM ; Gibco-BRL) containing 5 % foetal bovine serum (FBS ; Gibco-BRL). Strain 108 was used for challenge, whereas the Cooper strain was used for plaque assays and virus neutralization assays.
Plasmid construction. All enzymes used for cloning procedures were purchased from Amersham Pharmacia Biotech. Plasmid pMAS (Klinman et al., 2000 ; Krieg et al., 1998b ) (a gift from H. Davis, Coley Pharmaceutical Group, Ottawa, Canada) was modified by the introduction of specific CpG motifs based on the bovine immunostimulatory sequence (BIS) from ODN 2135 Uwiera et al., 2001b) . Briefly, two complementary oligodeoxynucleotides were annealed to form a duplex containing eight CpG motifs with 5h protuding ends complementary to the restriction enzyme AvaII (Fig. 1a) . These duplexes were force-directional cloned by random ligation into the AvaII site of pMAS. The number of inserts per plasmid was verified by restriction enzyme digestion and sequencing. Plasmids pBIS40 (40 motifs) and pBIS88 (88 motifs) were selected and further modified by inserting intron A downstream of the human cytomegalovirus immediate-early (HCMV IE) promoter. Intron A was isolated from pCAN1 (Uwiera et al., 2001a) using EagI and PstI (blunted with T4 DNA polymerase) and inserted into the pMAS and the CpG-modified vectors cut with EagI and EcoRV to create pMASIA, pBISIA40 and pBISIA88. Finally, the gene encoding tgD was isolated from pSLIAtgD (Braun et al., 1997) by BglII digestion and inserted into the adapted vectors at the BglII site to create pMASIA-tgD, pBISIA40-tgD and pBISIA88-tgD. Transient expression of the [$&S]methionine-labelled secreted tgD protein in COS-7 cells was confirmed by immunoprecipitation, followed by SDS-PAGE (Laemmli, 1970) and autoradiography, as previously described (van Drunen Littel-van den Hurk et al., 1984) .
Plasmid DNA for immunization was purified from Escherichia coli strain DH5α using anion exchange columns (Qiagen), treated to remove endotoxin by repeated Triton X-114 (Sigma) extraction as previously described (Cotten et al., 1994) , resuspended at 2n0 mg\ml in sterile endotoxin-free water (Gibco-BRL), and stored at k20 mC. Endotoxin levels in DNA stocks were verified as 0n10 EU\mg DNA ( 10 pg\mg DNA), using the Limulus amoebocyte lysate QLC-1000 kit (BioWhittaker).
Immunizations. BHV-1-seronegative calves (9 months old) were randomly sorted into four groups of seven animals and one group of five animals. The group with five animals received a commercial killed BHV-1 vaccine at the manufacturerhs recommended dose (Triangle 3jType II BVDV ; Ayerst). The remaining calves received 500 µg of pMASIA-tgD, pBISIA40-tgD, pBISIA88-tgD or saline (control group) in a 500 µl volume administered intradermally using the Biojector 2000 needle-free injection system (Bioject). All animals were reimmunized after 28 days. The experiment was conducted in accordance with the guidelines provided by the Canadian Council on Animal Care.
Challenge and clinical observations. Animals were challenged 20 days after secondary immunization, as previously described (Loehr et al., 2001a) . Briefly, each calf was exposed to a 4 min aerosol of 10( p.f.u.\ml of BHV-1 strain 108 generated by a DeVilbis Nebulizer, model 65 (DeVilbis). For 10 days after challenge, blinded clinical examinations, rectal temperatures and body weights were recorded.
Sampling. Sera were collected prior to primary and secondary immunization, before challenge and on days 4, 8 and 11 after challenge. Blood for the isolation of peripheral blood mononuclear cells (PBMCs) was collected 14 days after primary immunization, 14 days after secondary immunization and 11 days following challenge.
Virus isolation and quantification. Tampons were used to collect nasal fluid for virus titration 3 days before challenge and on days 2, 4, 6, 8, 10 and 12 after challenge. Virus secretion was determined by plaque assays in triplicate in 96-well plates (Nalge Nunc) with an antibody overlay as previously described (van Drunen Littel-van den .
Virus neutralization assays.
The virus neutralization titres in serum samples were determined as previously described and expressed as the highest reciprocal dilution of serum that resulted in a 50 % reduction in p.f.u. relative to the virus control (van Drunen Littel-van den Hurk et al., 1990) .
Lymphocyte proliferation assays. Blood was collected into citrate-dextran and PBMCs were isolated on Ficoll-Plaque Plus (Amersham Pharmacia Biotech) as previously described (Loehr et al., 2000) . PBMCs were cultured in 96-well plates (Nalge Nunc) at 3n5i10' cells\ml in 200 µl of MEM (Gibco-BRL) containing 10 % (v\v) heat-inactivated FBS (Gibco-BRL), 2 mM -glutamine (Gibco-BRL), 500 mg\ml gentamicin (Gibco-BRL), 1 mg\ml dexamethasone and 50 µM 2-mercaptoethanol (Bio-Rad), in triplicate wells containing medium alone or purified gD at 1 µg\ml. After 72 h in culture at 37 mC with 5 % CO # , the cells were pulsed by the addition of 0n4 µCi [methyl-$H]thymidine per well (Amersham Pharmacia Biotech) and harvested 18 h later. Incorporation of [$H]thymidine was measured using a liquid scintillation counter (Beckman 1701). Stimulation indices (SI) were calculated as the quotient of the mean counts per minute of the gDstimulated samples over that of the medium control.
IFN-γ ELISPOT assays.
Nitrocellulose plates (Millipore) were coated overnight with a bovine IFN-γ-specific monoclonal antibody (2-2-1) (Raggo et al., 2000) , washed and blocked for 1 h with medium. PBMCs in medium were dispensed at 10' cells per well in triplicate wells containing medium alone or gD at 0n4 µg\ml and incubated at 37 mC for 24 h. IFN-γ-secreting cells were labelled with a rabbit serum specific for bovine IFN-γ (lot 92-131) (Raggo et al., 2000) , followed by alkaline phosphatase (AP)-conjugated goat anti-rabbit IgG (HjL) (Kirkegaard and Perry Laboratories). Spots representing IFN-γ-secreting cells were visualized with BCIP-NBT substrate (Sigma). The number of INF-γ-secreting cells\10' PBMCs was expressed as the difference between the number of spots in the gD-stimulated wells and the number of spots in the medium control wells.
ELISAs.
Immulon 2 microtitre plates (Dynatech Laboratories) were coated overnight with tgD at 0n05 µg per well and incubated with CJHE serially diluted serum samples. AP-conjugated goat anti-bovine IgG (HjL) (Kirkegaard and Perry Laboratories) was used to detect total IgG. Isotyping was performed by indirect ELISA using IgG1-and IgG2-specific monoclonal antibodies (provided by K. Neilson, Animal Disease Research Institute, Nepean, ON, Canada) followed by AP-conjugated rabbit anti-mouse IgG (Kirkegaard and Perry Laboratories). Conjugates were used at a final dilution of 1 : 10 000 and the reactions were visualized with p-nitrophenyl phosphate (Sigma).
SDS-PAGE and Western blotting.
An aliquot containing 60 µg of purified BHV-1 strain 108 was run in a single-lane SDS-PAGE according to the Laemmli system (Laemmli, 1970) , transferred to a nitrocellulose membrane as recommended by the manufacturer (Bio-Rad) and incubated overnight at 4 mC in 3 % skimmed milk in Tris-buffered saline (TBS ; 10 mM Tris-HCl, pH 7n5, 170 mM NaCl). The membrane was mounted on to a slot blot apparatus (MiniPROTEAN II Multiscreen ; Bio-Rad) and incubated for 2 h with pooled pre-challenge and post-challenge serum (diluted 1 : 50 in 1 % skimmed milk in TBS) from each group. The membrane was washed three times in TBS and incubated for 1 h with AP-conjugated goat anti-bovine IgG (diluted 1 : 5000 in 1 % skimmed milk in TBS). Seroreactive proteins were visualized using BCIP-NBT.
Statistical analysis. All data were analysed with the aid of Graphpad Prism 2.0. Differences between groups in the proliferation, neutralization, isotype ratio, ELISA and ELISPOT assays were examined by one-way analysis of variance (ANOVA) and Dunnetths test. Virus shedding, weights and temperatures were analysed by one-way ANOVA and Tukeyhs multiple comparison test.
Results

Expression of tgD from CpG-enhanced vectors
Plasmid pMASIA was enhanced with respect to CpG content by the addition of multiple copies of annealed complementary synthetic ODNs based on the sequence of the pan-activating ODN 2135 Rankin et al., 2001 ). This cloning step was designed to control the orientation of the insert, but the number of inserts cloned per plasmid was a random event. Therefore, clones were screened by digestion with restriction enzymes AvaII and DraI, which flank the CpG-containing insert, and by sequencing. Vectors pMASIA, pBISIA40 and pBISIA88 were selected, and the gene encoding BHV-1 tgD was inserted to create pMASIA-tgD (Fig. 1b) , pBISIA40-tgD and pBISIA88-tgD. All constructs were verified by restriction digestion (Fig. 1c) and sequencing.
Expression of tgD from these vectors was confirmed by transient transfection of COS-7 cells. The $&S-labelled tgD gene product, which is secreted into the culture medium, was visualized by SDS-PAGE and autoradiography of immunoprecipitated supernatants. The molecular mass and relative gel mobility (Fig. 1d ) of the tgD protein was consistent with previous reports (van Drunen Littel-van den Hurk et al., 1994 . 
Cellular immune responses
Antigen-specific proliferation elicited by immunization with plasmid-encoded tgD tended to be superior to that induced by the killed vaccine (Fig. 2a) . The stimulation index (SI) was 5 in all groups 14 days after primary immunization. Secondary immunization enhanced the proliferative response by day 42 in the DNA-immunized groups in a CpG dosedependent manner, correlating positively with the number of CpG motifs per plasmid. However, only the group that received pBISIA88-tgD displayed an SI that was significantly greater (P 0n05) than that of the saline control group and the group that received the killed vaccine. All groups exhibited an increased antigen-specific proliferative response following challenge, with the pBISIA88-tgD-immunized group having a significantly greater (P 0n05) SI than the saline and killed vaccine groups (Fig. 2a) .
Antigen-specific IFN-γ production by PBMCs was assessed to confirm the induction of a cellular immune response (Fig.  2b) . Within 14 days of the primary vaccination, the groups immunized with pBISIA40-tgD or pBISIA88-tgD had significantly greater (P 0n05) numbers of IFN-γ-secreting cells than the saline group, so the CpG dose-dependent trend that was observed in the proliferation assay was also observed in the IFN-γ response. This trend was enhanced after secondary immunization, as all three DNA-immunized groups had a significantly greater (P 0n05) number of IFN-γ-secreting cells than the saline control group. Similar to the antigen-specific proliferative response, the group immunized with pBISIA88-tgD had a significantly greater (P 0n05) number of IFN-γ-secreting cells than the killed vaccine group. Following challenge, the number of antigen-specific IFN-γ-secreting cells increased in the saline group, while numbers in the other groups were similar to pre-challenge levels. Nevertheless, there were significantly more (P 0n05) IFN-γ-secreting cells in the PBMCs of the pBISIA40-tgD and pBISIA88-tgD groups than in the PBMCs of the saline and killed vaccine groups. However, there was no significant differences in cellular immune responses between DNA-vaccinated groups.
Humoral immune responses
The tgD-specific total serum IgG response to primary immunization was similar in all groups, with only the pMASIAtgD-and pBISIA88-tgD-immunized groups having a significantly greater (P 0n01) titre than the control group (Fig. 3a) . After secondary immunization, the groups immunized with plasmid encoding tgD had an antigen-specific titre significantly greater (P 0n05) than the titre of the saline control group when tested on day 48. The group that received the killed vaccine had the greatest increase (P 0n01) in tgD-specific titres relative to the saline control group after the secondary immunization. The IgG1 : IgG2 ratio of tgD-specific serum antibody was determined to evaluate the type of response to immunization. When compared with all other immunized groups, the pBISIA88-tgD-immunized group had a significantly lower (P 0n05) IgG1 : IgG2 ratio (Fig. 3c) .
By 8 days after challenge, all of the immunized groups displayed an anamnestic response significantly greater (P 0n01, pBISIA40-tgD ; P 0n001, other groups) than the saline group. The pMASIA-tgD-and pBISIA88-tgDimmunized groups had significantly greater titres than the pBISIA40-tgD group (P 0n001). When compared with the group that received the killed vaccine, the pMASIA-tgD-and pBISIA88-tgD-immunized groups also showed a significantly greater anamnestic response (P 0n05 and P 0n01, respectively).
To evaluate the effectiveness of the anamnestic responses, the level of BHV-1 neutralizing antibodies in serum was assayed on days 0, 4, 8 and 11 after challenge (Fig. 3b) . On the day of challenge, the pBISIA88-tgD-and killed-vaccineimmunized groups had a neutralizing antibody titre that was significantly greater (P 0n05) than that of the saline group. After 8 days, all vaccinated groups had significantly greater (P 0n05) neutralization titres than the saline control group, with the pBISIA88-tgD-immunized group having the greatest titre (P 0n01). By day 12, all immunized groups had a nearly CJHG CpG-enhanced vectors for DNA immunization CpG-enhanced vectors for DNA immunization Fig. 3 . Humoral immune responses. (a) tgD-specific antibody titres as determined by ELISA. Results are expressed as the reciprocal of the highest dilution resulting in a reading of two standard deviations above the control value. The values displayed are the geometric means for each grouppSD. Significance of differences from the mean of the saline group is as indicated (*, P 0n05 ; **, P 0n01 ; ***, P 0n001). On day 56, tgD-specific titres for pMASIA-tgD and pBISIA88-tgD were significantly greater (P 0n05) than tgD-specific titres for Triangle. (b) Virus neutralization titres in sera after challenge. Results are expressed as the 50 % end-point using 100 p.f.u. of BHV-1. Significance of differences from the mean of the saline group is as indicated (*, P 0n05 ; **, P 0n01). (c) Serum isotype ratio on the day of challenge. Results for each group represent the average ratiopSEM. Significance of the difference of the mean of the pBISIA88-tgD-treated group from the mean of other groups is indicated (*, P 0n05). (d) Specificity of the humoral immune response. S, saline ; 0, pMASIA-tgD ; 40, pBISIA40-tgD ; 88, pBISIA88-tgD ; T, Triangle ; P, pre-challenge pooled serum ; C, post-challenge pooled serum from each group. Glycoproteins with apparent molecular masses corresponding to gD and d-gD (dimeric) are indicated. equivalent neutralization titre, and titres remained significantly greater than that of the control group (P 0n01).
A Western blot was performed using pooled pre-challenge (day 48) and post-challenge (day 54) sera from each group to determine which BHV-1 proteins were seroreactive (Fig. 3d) . The DNA-immunized groups developed a tgD-specific humoral response that detected both the monomeric (71 kDa) and dimeric (142 kDa) forms of the glycoprotein. In contrast, the group that received the killed vaccine developed a broad humoral immune response against several BHV-1 proteins in addition to gD (van Drunen Littel-van den Hurk & Babiuk, 1986 ; Whitbeck et al., 1996) . After challenge, all immunized groups demonstrated an increase in the level of the antigenspecific humoral response.
Clinical response to BHV-1 challenge
On the day of challenge, and for the next 12 days, all animals were sampled and monitored to evaluate the protection achieved by immunization. Nasal secretions were collected on days 0, 2, 4, 6, 8, 10 and 12 and assayed for BHV-1 shedding (Fig. 4a) . Virus shedding was greatest in the salinetreated group and lasted for at least 10 days. The killedvaccine-and pBISIA88-tgD-treated groups had a significantly lower (P 0n05) level of shedding than the saline control group on day 6, and by day 8 all the immunized groups displayed significantly lower (P 0n05) shedding than the control group.
Clinical evaluation of all animals was performed for 10 days post-challenge. No animals exhibited breathing difficulty or developed nasal lesions (data not shown). Most animals experienced weight loss, with the exception of the killedvaccine-immunized group, which performed significantly better (P 0n05) than the other groups and maintained a steady weight gain for the 10 days after challenge (Fig. 4b) .
Another clinical symptom used to measure the host response to challenge was the change in body temperature. By Significance (*, P 0n05 ; **, P 0n01) of differences from the mean are as indicated for the saline group (a) or the Triangle group (b) and (c).
day 2 after challenge, a temperature increase was measured in the saline-and DNA-immunized groups that was significantly greater (P 0n05) than that in the killed-vaccine-immunized group (Fig. 4c) . As expected, the saline control group had the greatest and longest temperature increase. After 10 days, the temperatures of all animals had returned to normal.
Discussion
This is the first report describing the potential of a CpGenhanced DNA vaccine to elicit augmented immune responses against an economically important pathogen in a large animal species. Phosphorothioate ODNs that contain the GTCGTT motif have been shown to be immunostimulatory for immune cells from several vertebrate species and have also been shown to have unique adjuvant effects when administered with proteins in ruminants Rankin et al., 2001 Rankin et al., , 2002 . Here, we have shown that antigen-expressing DNA vectors with multiple copies of the GTCGTT motif incorporated into the backbone are more effective at inducing a cellular immune response in cattle than a vector without the CpG motif. The insertion of CpG motifs into the vector did not appear to affect the level of antigen-specific antibody. Nevertheless, insertion of a high level of CpG motifs in the vector backbone significantly reduced the IgG1 : IgG2 ratio in serum antibody and also enhanced virus neutralization titres. In addition to the IgG1 : IgG2 shift, insertion of CpG motifs into the vector enhanced antigen-specific lymphocyte proliferation and IFN-γ secretion by PBMCs. Indeed, there was a direct, albeit not statistically significant, correlation between the number of CpG motifs inserted and the magnitude of the cellular response. Finally, animals immunized with the DNA vaccines, pBISIA88-tgD in particular, cleared the virus more rapidly after challenge. Therefore, CpG motifs are able to enhance the cellular immune response in cattle as part of the plasmid backbone and as a phosphorothioate ODN , making CpG motifs an excellent adjuvant for use in either application.
There are two essential features that all expression vectors used for vaccination must have. The first is the adjuvant properties of the plasmid backbone as determined by the balance of immunostimulatory and inhibitory CpG motifs (Klinman et al., 2000 ; Krieg et al., 1998b) . Plasmid pMAS was used as the starting material because it has undergone extensive modification to remove over 50 inhibitory CpG motifs and because it contains a specific site designed for the directional insertion of DNA fragments (Klinman et al., 2000 ; Krieg et al., 1998b) . For this study, multiple copies of the pan-activating 5h GTCGTT 3h motif were inserted because it has been shown to be immunostimulatory in several species Rankin et al., 2001) .
The second feature is a transcriptional unit able to express the antigen-encoding gene at high levels. The most commonly used expression cassette is the HCMV IE promoter with the bovine growth hormone polyadenylation signal. This expression system was further optimized by the addition of the HCMV intron A downstream of the IE promoter. Intron A has been shown to enhance the antibody response in cattle immunized with tgD-encoding plasmid (Braun et al., 1997) . Furthermore, intron A is essential for the expression of genes from RNA viruses and bacteria that are not normally CJHI transcribed in the nucleus of a eukaryotic cell (van Drunen Littel-van den Hurk et al., 1999) . Overall, addition of intron A and the enrichment for immunostimulatory CpG motifs should make pMASIA and the pBISIA vectors a robust DNA vaccination system for numerous pathogens in many host species.
The role played by the plasmid backbone in the induction of an immune response to DNA vaccination is not well defined. It has been suggested that CpG motifs are essential for developing an effective immune response following vaccination via the intradermal route (Sato et al., 1996) . In that study, mice administered a vector expressing β-galactosidase that had one or two additional palindromic 5h AACGTT 3h motifs had stronger humoral and cellular immune responses than vectors without the motifs. This study also suggested that the increased immune response induced by the adjuvant properties of CpG motifs is, to some extent, counter-balanced by down-regulation of gene expression by the increased expression of pro-inflammatory cytokines. Krieg et al. (1998a) also suggested that down-regulation of the HCMV IE promoter was responsible for an increase, plateau and drop in antibody titres in mice immunized with vectors containing 0, 16 or 50 CpG motifs per plasmid. Nevertheless, in that study the CTL activity in splenocytes was positively correlated with the number of CpG motifs per plasmid.
The size of the immunized animal may have a significant bearing on the outcome of DNA immunization. In the mouse experiments described above, the amount of plasmid, and therefore the number of CpG motifs, administered per body weight is far in excess of what we have used in cattle. This could explain why we observed that the number of CpG motifs per plasmid had no significant effect on the total tgD-specific antibody titre before challenge. However, there was a dramatic decrease in the ratio of IgG1 : IgG2 antibodies in the group immunized with pBISIA88-tgD. Therefore, the additional CpG motifs had a significant qualitative effect on the humoral response, but this was not observed until the CpG content of the vector exceeded 40 motifs. This suggests that a critical threshold of CpG motifs may be required to significantly influence the IgG isotype ratio in large animals such as cattle, while there is a more CpG dose-dependant correlation with cellular immune responses.
Prior to and following challenge, the host response in the pBISIA40-tgD-vaccinated group was lower than expected. This trend could be seen in the lymphocyte proliferative response (Fig. 2a) , virus neutralization titres (Fig. 3b) and in the intensity of the staining of gD in the Western blot (Fig. 3d) . However, it was especially evident in the total gD-specific IgG titres on day 56, where the pBISIA40-tgD treated group was significantly lower than the pMASIA-tgD-and pBISIA88-tgDtreated groups (Fig. 3a) . One possible explanation for this observation is that although each plasmid expressed tgD at similar levels in vitro (Fig. 1d) , there is evidence that the HCMV promoter on plasmids with 50 CpG motifs is down-regulated in mice due to the increase in proinflammatory cytokines induced by CpG motifs (Krieg et al., 1998a ; Sato et al., 1996) . Therefore, it is plausible that pBISIA40-tgD is also affected by down-regulation in cattle when compared with pMASIA-tgD, and that this is overcome by additional CpG motifs present in pBISIA88-tgD.
Intradermal delivery of plasmid-encoded tgD has previously been shown to be an effective route for vaccination in cattle (Braun et al., 1997) . It is possible that the titres attained in this study are approaching the upper limit for this model system. Increasing the CpG content of the plasmid backbone in combination with approaches such as electroporation, vector targeting and antigen targeting could be used to increase antibody titres beyond those shown here.
Despite the augmentation of the cellular immune response and virus neutralization titres, the CpG-enhanced plasmids did not offer enhanced protection from virus challenge when compared with the killed vaccine. This can be explained in part by the choice of disease model. It has been established that even though a cellular response to infection is important, prevention from BHV-1 infection is more positively correlated with a strong antibody response (Babiuk et al., 1995 ; Loehr et al., 2000 Loehr et al., , 2001b . Thus, even though the CpG-enhanced vectors did augment the cellular immune response, this did not provide additional protection from challenge. Other important bovine pathogens, such as bovine viral diarrhoea virus, bovine respiratory syncytial virus and Mycobacterium bovis, require strong cellular immune responses for recovery (Buddle, 2001 ; Rhodes et al., 1999 ; Taylor et al., 1995) . Therefore, CpGenhanced DNA vaccine vectors could be effective in preventing these infectious diseases.
In addition to the disease model chosen, it is important to clarify that the killed vaccine used in this study carries several BHV-1 antigens in addition to gD, the lone antigen in the DNA vaccine formulations. Indeed, a Western blot revealed that both pre-and post-challenge serum from the DNAvaccinated groups specifically recognized gD, while the group that received the killed vaccine recognized several BHV-1 proteins (Fig. 4d) . BHV-1 glycoproteins gB and gC have been shown to be protective in BHV-1 challenge models (Babiuk et al., 1987) . Therefore, we concluded that the additional protective antigens in the killed vaccine formulation probably contributed to the protective immunity demonstrated here. Plasmids with engineered genes encoding immunodominant epitopes from several BHV-1 antigens could be used to induce a broader, and perhaps more protective, immune response with DNA immunization.
In conclusion, we have shown that CpG-enhanced vectors are able to augment the cellular immune responses in a bovine disease challenge model. This work confirms previously published observations that enhanced cellular immunity to BHV-1 is not correlated with protection unless a strong humoral response is induced as well. These data lay the foundations for future studies that will investigate the efficacy
